Clinical trials: Metastatic Malignant Neoplasm
Pancreatic Cancer
Phase I TH-302 Plus Gemcitabine Plus Nab-Paclitaxel in Pancreatic Cancer
This is a multicenter, open-label, Phase 1, dose escalation trial to evaluate the safety, tolerability, and recommended Phase 2 dose (RP2D) of TH-302 in combination with gemcitabine and nab-paclitaxel in previously untreated…
- Trial name
- NCT02047500
- Testing
- TH-302, Nab-paclitaxel, Gemcitabine
- Where
- 5 sites in United States
- Volunteers
- 19 people
- Sponsor
- ImmunoGenesis
Non-Small Cell Lung Cancer
Iressa 2nd Line Phase III Study in Japan
In this study, among the patients with non-small cell lung cancer, those with metastasis or recurrence and previous treatment with chemotherapy will receive gefitinib or docetaxel, and we will compare the effectiveness and safety…
- Trial name
- NCT00252707
- Testing
- Gefitinib or Docetaxel
- Where
- 40 sites in Japan
- Volunteers
- 484 people
- Sponsor
- AstraZeneca
Metastatic Breast Cancer, Advanced Breast Cancer
Implementing Patients´ Competence in Oral Breast Cancer Therapy
The aim of the IMPACT - Implementing Patients' competence in oral breast cancer therapy - study is to evaluate the effectiveness of a standardized patient education and coaching and optional eMBSR for therapy management provided…
- Trial name
- IMPACT (NCT04030728)
- Volunteers
- 212 people
- Sponsor
- Onco Medical Consult GmbH
PDAC, PDAC - Pancreatic Ductal Adenocarcinoma
TNG462-C103: Study to Evaluate the Safety, Tolerability, and Antitumor Activity of Vopimetostat in Combination With ERAS-0015 in PDAC and NSCLC Patients
TNG462-C103 is a Phase 1/2 study to investigate the safety and antitumor activity of vopimetostat (TNG462) combined with ERAS-0015 in patients with MTAP-null pancreatic or MTAP-null non-small cell lung cancer with RAS mutation.
- Conditions
- PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, NSCLC, RAS Mutation
- Trial name
- NCT07897734
- Testing
- vopimetostat, ERAS-0015
- Volunteers
- 188 people
- Sponsor
- Tango Therapeutics, Inc.
Squamous Cell Carcinoma of Head and Neck (SCCHN), Metastatic Colorectal Cancer
Study of Safety and Efficacy of INC280 and Cetuximab, in Adult c-MET Positive mCRC and HNSCC Patients After Progression on Cetuximab or Panitumumab Therapy
This was an open-label, phase Ib, multicenter clinical trial to determine the MTD/RDE of the orally administered c-MET inhibitor INC280 in combination with cetuximab.
- Trial name
- NCT02205398
- Testing
- INC280, cetuximab
- Where
- 15 sites in United States, Belgium and 5 more
- Volunteers
- 13 people
- Sponsor
- Novartis Pharmaceuticals
Advanced Solid Tumor, Metastatic Solid Tumor
BGB-A3055 Alone and in Combination With Tislelizumab in Participants With Solid Tumors
This study aims to evaluate how safe and well-tolerated the treatment is, how the body processes it, how it works on the tumors, and whether it shows early signs of fighting cancer in people with certain advanced or metastatic…
- Conditions
- Advanced Solid Tumor, Metastatic Solid Tumor, Solid Tumor
- Trial name
- NCT05935098
- Testing
- BGB-A3055, Tislelizumab, Chemotherapy
- Where
- 26 sites in United States, Australia and 3 more
- Volunteers
- 99 people
- Sponsor
- BeiGene
Locally Advanced or Metastatic Solid Tumors, Non-small Cell Lung Cancer
HLX301 (TIGIT×PDL1 Bispecific) in Patients With Locally Advanced or Metastatic Solid Tumors
This Phase 1/2, multicenter, first-in-human, open-label, dose-escalation, dose expansion, and clinical expansion study will evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-tumor efficacy of HLX301…
- Trial name
- NCT05102214
- Testing
- HLX301
- Where
- 5 sites in Australia
- Volunteers
- 150 people
- Sponsor
- Shanghai Henlius Biotech
Locally Advanced Solid Tumor, Metastatic Solid Tumor
A Phase 1 Study to Assess the Effect of Hepatic Impairment on the Pharmacokinetics of Repotrectinib in Advanced Cancer Patients
This is a Phase 1 study to evaluate the effect of moderate or severe hepatic impairment on the PK of repotrectinib in patients with advanced cancer.
- Trial name
- NCT05828277
- Testing
- repotrectinib (TPX-0005)
- Where
- 2 sites in United States, Spain
- Sponsor
- Turning Point Therapeutics, Inc.
Metastatic Melanoma
Dose Escalation Study of MLN4924 in Adults With Melanoma
This is an open-label, multicenter, phase 1, dose escalation study that will evaluate the safety profile, establish Maximum Tolerated Dose (MTD), and inform the recommended phase 2 dose of MLN4924 as well as evaluate antitumor…
- Trial name
- NCT01011530
- Testing
- MLN4924
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
NSCLC, EGFR Activating Mutation
Phase III Study of TY-9591 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLETEO)
To assess the efficacy and safety of TY-9591 versus Osimertinib in patients with locally advanced or Metastatic Non Small Cell Lung Cancer.
- Trial name
- NCT05382728
- Testing
- TY-9591, Osimertinib
- Where
- 2 sites in China
- Volunteers
- 680 people
- Sponsor
- TYK Medicines, Inc
Second-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
SHR-A1904 Compared With Investigator's Choice of Therapy in Claudin18.2 Positive Patitens With Second-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
The study evaluated the overall survival (OS) of SHR-A1904 versus investigator-selected treatment in second-line CLDN18.2-positive advanced GC/GEJC patients
- Trial name
- NCT06649292
- Testing
- SHR-A1904, Paclitaxel, Docetaxel, Irinotecan
- Where
- China
- Volunteers
- 524 people
- Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
Pancreatic Cancer
A Study of Erlotinib in Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer
This open-label, single-arm, multicenter trial is designed to evaluate the safety of erlotinib in combination with standard of care chemotherapy (gemcitabine) in participants with locally advanced, unresectable, or metastatic…
- Trial name
- NCT02694536
- Testing
- Erlotinib, Gemcitabine
- Where
- 11 sites in Italy
- Volunteers
- 80 people
- Sponsor
- Hoffmann-La Roche
Non Small Cell Lung Cancer
Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC
The main purpose of the study is to evaluate safety and efficacy of taletrectinib (also known as AB-106 or DS-6051b) monotherapy in the treatment of advanced NSCLC.
- Trial name
- TRUST-II (NCT04919811)
- Testing
- Taletrectinib
- Where
- 77 sites in United States, Canada and 7 more
- Volunteers
- 217 people, healthy volunteers welcome
- Sponsor
- Nuvation Bio Inc.
Metastatic Pancreatic Cancer
Cetuximab and Bevacizumab With or Without Gemcitabine to Treat Metastatic Pancreatic Cancer
Eligible patients with metastatic pancreatic cancer will be treated with dual agent monoclonal antibody consisting of cetuximab and bevacizumab alone or in combination with gemcitabine
- Trial name
- NCT00326911
- Testing
- cetuximab, bevacizumab, gemcitabine
- Where
- 16 sites in United States
- Volunteers
- 61 people
- Sponsor
- Eli Lilly and Company
Breast Neoplasms
Study to Assess the Efficacy and Safety of the Epigenetic Modifying Effects of CC-486 (Oral Azacitidine) in Combination With Fulvestrant
The purpose of this study to Assess the Efficacy and Safety of the Epigenetic Modifying Effects of CC-486 (Oral Azacitidine) in Combination With Fulvestrant in Postmenopausal Women with estrogen receptor positive (ER+), human…
- Trial name
- NCT02374099
- Testing
- CC-486, Fulvestrant
- Where
- 35 sites in United States, Belgium and 4 more
- Volunteers
- 97 people
- Sponsor
- Celgene
Metastatic Solid Tumors
SLR-108 PET Imaging in Subjects With Metastatic Solid Tumors
This is a Phase 1 study evaluating the feasibility of using SLR-108 for positron-emission tomography (PET) imaging of metastatic solid tumors.
- Trial name
- NCT07728942
- Testing
- SLR-108, SLX-1411
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Solve Therapeutics
Advanced Solid Tumors
The Primary Objective of This Study to Evaluate the Safety and Tolerability of IBI334 and Determine the Maximum Tolerated Dose (MTD) and the Recommended Phase 2 Dose (RP2D)and Anti Tumor Activity of IBI334.
This is open-label, multicenter, Phase I/II study is designed to evaluate the Safety and tolerability and Efficacy of IBI334 Monotherapy in participants with advanced solid tumors.
- Trial name
- NCT05774873
- Testing
- IBI334
- Where
- China
- Volunteers
- 28 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Endometrial Cancer
Study of BN83495 in Post-menopausal Women With Endometrial Cancer Post-chemotherapy
The purpose of the protocol is to determine the effect of BN83495 on the progression of endometrial cancer with estrogen receptor in post menopausal women who had previously received chemotherapy.
- Trial name
- NCT01251354
- Testing
- BN83495
- Where
- 9 sites in United States, Canada
- Volunteers
- 6 people
- Sponsor
- Ipsen
Solid Tumor, Adult, Epithelial Ovarian Cancer
Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors
This is a first-in-human, Phase 1/2 open-label, multicenter, dose-escalation, safety, pharmacokinetics (PK), and biomarker study of CBX-12 in subjects with advanced or metastatic refractory solid tumors.
- Conditions
- Solid Tumor, Adult, Epithelial Ovarian Cancer, Small Cell Lung Carcinoma, Breast Cancer
- Trial name
- NCT04902872
- Testing
- CBX-12
- Where
- 4 sites in United States
- Volunteers
- 69 people
- Sponsor
- Cybrexa Therapeutics
HER2-positive Breast Cancer
RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive
The purpose of this study is to assess the efficacy and safety of RO7771950 in combination with trastuzumab and capecitabine, compared to tucatinib in combination with trastuzumab and capecitabine.
- Trial name
- BREnnA (NCT07413939)
- Testing
- RO7771950, Tucatinib, Trastuzumab
- Where
- 206 sites in United States, Argentina and 23 more
- Volunteers
- 650 people
- Sponsor
- Hoffmann-La Roche
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.